SAN DIEGO–(BUSINESS WIRE)–QuidelOrtho Company (Nasdaq: QDEL) (the Firm or QuidelOrtho), a worldwide supplier of progressive in vitro diagnostics applied sciences designed for point-of-care settings, scientific labs and transfusion drugs, introduced right this moment the pricing of the beforehand introduced underwritten secondary providing (the Providing) by Carlyle Companions VI Cayman Holdings, L.P. (the Promoting Stockholder) of 8,260,183 shares of the Firm’s widespread inventory (Widespread Inventory).
The Promoting Stockholder will obtain the entire proceeds from the Providing. The Firm shouldn’t be promoting any shares of Widespread Inventory within the Providing and won’t obtain any proceeds from the Providing.
Goldman Sachs & Co. LLC is performing as the only real underwriter of the Providing. The Providing is anticipated to shut on November 21, 2024, topic to customary closing circumstances.
Goldman Sachs & Co. LLC will provide the shares of Widespread Inventory to the general public at a set value, which can be modified at any time with out discover.
The Providing is being made pursuant to an efficient shelf registration assertion (together with a prospectus) filed by the Firm with the U.S. Securities and Trade Fee (SEC). A remaining prospectus complement and accompanying prospectus describing the phrases of the Providing will likely be filed with the SEC, copies of which can be obtained, when obtainable, from Goldman Sachs & Co. LLC, Consideration: Prospectus Division, 200 West Avenue, New York, NY, 10282, cellphone quantity: (866) 471-2526, or by e mail at prospectus-ny@ny.e mail.gs.com. These paperwork might also be obtained freed from cost by visiting EDGAR on the SEC’s web site at www.sec.gov.
This press launch doesn’t represent a suggestion to promote or the solicitation of a suggestion to purchase these securities, nor shall there be any sale of those securities in any state or jurisdiction through which such provide, solicitation or sale can be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.
Cautionary Observe Regarding Ahead Wanting Statements
This press launch incorporates forward-looking statements throughout the which means of the Personal Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Trade Act of 1934, as amended. These statements are any assertion contained herein that isn’t strictly historic, together with, however not restricted to, statements concerning the anticipated sale of Widespread Inventory by the Promoting Stockholder within the Providing. With out limiting the foregoing, the phrases could, will, would, ought to, would possibly, anticipate, anticipate, imagine, estimate, plan, intend, purpose, undertaking, technique, future, proceed or related phrases, expressions or the destructive of such phrases or different comparable terminology are supposed to establish forward-looking statements. Such statements are primarily based on the beliefs and expectations of QuidelOrtho’s administration as of right this moment and are topic to vital recognized and unknown dangers and uncertainties. Precise outcomes or outcomes could differ considerably from these set forth or implied within the forward-looking statements. The elements mentioned in QuidelOrtho’s Annual Report on Type 10-Okay for the fiscal yr ended December 31, 2023 and subsequent experiences filed with the SEC, together with underneath Half I, Merchandise 1A, Danger Components of the Type 10-Okay, amongst others, may trigger precise outcomes to vary from these set forth or implied within the forward-looking statements. You shouldn’t depend on forward-looking statements as predictions of future occasions as a result of these statements are primarily based on assumptions that will not come true and are speculative by their nature. All forward-looking statements are primarily based on info at present obtainable to QuidelOrtho and communicate solely as of the date hereof. QuidelOrtho undertakes no obligation to replace any of the forward-looking info or time-sensitive info included on this press launch, whether or not because of new info, future occasions, modified expectations or in any other case, besides as required by regulation.
About QuidelOrtho Company
QuidelOrtho Company (Nasdaq: QDEL) is a world chief in in vitro diagnostics, growing and manufacturing clever options that rework information into understanding and motion for extra individuals in additional locations day-after-day.
Providing industry-leading experience in immunoassay and molecular testing, scientific chemistry, and transfusion drugs, bringing quick, correct and dependable diagnostics when and the place they’re wanted – from house to hospital, lab to clinic. In order that sufferers, clinicians and well being officers can spot developments sooner, reply faster and chart the course forward with accuracy and confidence.
Constructing upon its a few years of groundbreaking innovation, QuidelOrtho continues to associate with clients throughout the healthcare continuum and across the globe to forge a brand new diagnostic frontier. One the place insights and options know no bounds, experience seamlessly connects and a extra knowledgeable path is illuminated for every of us.
QuidelOrtho is advancing diagnostics to energy a more healthy future.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20241119268143/en/
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
D. Nikki Wheeler
Senior Director, Company Communications
media@QuidelOrtho.com
Supply: QuidelOrtho Company
